Division of Daiichi Sankyo Co. Ltd.
Latest From Plexxikon Inc.
Attempts to maximize the current commercial portfolio and prepare for upcoming pipeline launches spell more job losses at the US arm of major Japanese pharma Daiichi Sankyo.
Daiichi Sankyo says it is “committed to a major transformation in oncology” as it prioritizes and pursues projects in this field under a new team leader, who chose to highlight unique antibody-drug conjugate technology and the acute myeloid leukemia franchise at a recent R&D Day in Tokyo.
Daiichi Sankyo is to continue with a multinational Phase III trial for its novel candidate for tenosynovial giant cell tumor despite cases of liver toxicity, but has stopped enrolment short of target and modified the protocol.
"I love it when a plan comes together," Hannibal Smith of TV show The A-Team used to say, a catchphrase which Daiichi Sankyo will be hoping is appropriate in around five years' time as it looks back on the results of its new mid-term strategy.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Daiichi Sankyo Co. Ltd.
- Senior Management
K. Peter Hirth, PhD, CEO
Kathleen Sereda Glaub, Pres.
Gideon E Bollag, PhD, SVP, Research
- Contact Info
Phone: (510) 647-4000
91 Bolivar Dr.
Berkeley, CA 94710
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.